Brief: Shenzhen Hepalink Pharmaceutical Posts QTRLY Net Profit Attributable Of RMB234.9 Million
29/04/2022 12:26
April 29 (Reuters) - Shenzhen Hepalink Pharmaceutical Group
Co Ltd 002399.SZ :
* QTRLY NET PROFIT ATTRIBUTABLE RMB234.9 MILLION VERSUS
RMB143.5
MILLION
* QTRLY OPERATING REVENUE RMB1.91 BILLION VERSUS RMB1.27
BILLION
Source text for Eikon: urn:newsml:reuters.com:*:nHKS1wBmBk
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA